About US
Contact us
-
GlaxoSmithKline taps breath data analyzer to improve COPD patient selectionGlaxoSmithKline is once again getting techy with its clinical trial improvement efforts. The company will incorporate Owlstone Medical’s Breath Biopsy platform, which analyzes biomarkers from breat2017/11/24
-
Acadia launches Parkinson’s campaign to shine light on psychosis symptomsA new disease awareness campaign shines a light on the hallucinations and delusions that can affect half of people who have Parkinson’s disease. Sponsored by Acadia Pharmaceuticals, a TV ad and acc2017/11/24
-
GlaxoSmithKline taps breath data analyzer to improve COPD patient selectionGlaxoSmithKline is once again getting techy with its clinical trial improvement efforts. The company will incorporate Owlstone Medical’s Breath Biopsy platform, which analyzes biomarkers from breat2017/11/23
-
AmerisourceBergen says civil penalty to resolve DOJ probe now at $625MIt turns out that the quarter-crushing $575 million that drug wholesaler AmerisourceBergen set aside to settle civil litigation with the Justice Department was not enough. It is going to take another2017/11/23
-
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefitsLast year, real-world data showed that SGLT2 diabetes drugs could significantly cut heart failure hospitalizations and all-cause deaths. And now, a new analysis shows they can also cut the rate of maj2017/11/22
-
Not over till it’s over: Pharma ad police issue another warning, this time to Amherst and MagnaIt turns out pharma's ad police aren't done doling out warnings in a year that's seen a historic few. The FDA's Office of Prescription Drug Promotion issued another warning last week, bringing its tot2017/11/22
-
Concordia catches antitrust scrutiny over 5,700% price rise for thyroid drugConcordia Healthcare has already caught the ire of government watchdogs and pharmacy benefits managers for its price hikes. Now, add one more investigation to its list: A U.K.antitrust probeinto its p2017/11/21
-
With $2.5B in Herceptin sales on the line, Roche sues Pfizer for biosim patent infringementBringing biosimilars to market isn't an easy proposition, as Pfizer and its fellow biosimilar makers continue to discover. In another hurdle Pfizer will have to clear, Roche has sued for infringement2017/11/21
-
Intense EMA campaign ends in chance: Amsterdam selected for HQ over Milan after a tieWith all eyes fixed on Monday's vote for the European Medicines Agency relocation, Amsterdam emerged as thewinnerfor the new headquarters ahead of other finalists Milan and Copenhagen. Nineteen E2017/11/20
-
Pfizer in fight with states over their intent to use its drugs for executionsPfizer is in a tug of war with several states that intend to use some of its drugs to carry out executions. The drugmaker sent letters last month to both Nevada and Nebraska asking for the return o2017/11/20